Working… Menu

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03634332
Recruitment Status : Recruiting
First Posted : August 16, 2018
Last Update Posted : May 7, 2019
Merck Sharp & Dohme Corp.
Halozyme Therapeutics
University of Washington
Information provided by (Responsible Party):
Pancreatic Cancer Research Team